 |
||
|
NEWS RELEASES Aug. 10, 2009 Vancouver, British Columbia – August 10, 2009 – Upstream Biosciences Inc. (OTCBB: UPBS) today announced that the company is actively seeking licensors or acquirers for its novel anti-parasitic drug discovery portfolio and cancer diagnostic platform... July 24, 2009 Oct. 7, 2008 Oct. 1, 2008 Sept. 15, 2008 July 9, 2008 June 25, 2008 June 10, 2008 April 28, 2008 April 17, 2008 April 10, 2008 Mar 25, 2008 Mar 10, 2008 Feb 20, 2008 Feb 6, 2008 Jan 9, 2008 Upstream Biosciences Inc. (OTCBB: UPBS) today announced that it has entered into a collaboration with the Combinatorial Chemistry Center of the Chemistry Department of Lomonosov Moscow State University (MSU) in Moscow, Russia for the chemical synthesis of novel compounds that Upstream intends to test for efficacy and toxicity against tropical parasitic diseases, including malaria, leishmaniasis and trypanosomiasis, or African sleeping sickness, as well as for cancer indications... Jan 3, 2008 Vancouver, British Columbia– January 3, 2008– Upstream Biosciences Inc. (OTCBB: UPBS) today announced that it has entered into a collaboration with the Provincial Laboratory for Public Health (or ProvLab) in Alberta, Canada to begin in vitro testing of Upstream’s novel compounds for the potential treatment of malaria... Dec 17, 2007 Vancouver, British Columbia– December 17, 2007– Upstream Biosciences Inc. (OTCBB: UPBS) today announced that it has entered into a collaboration with Makerere University in Kampala, Uganda with whom we plan to begin in vivo efficacy and toxicity testing of our novel compounds for the treatment of trypanosomiasis, or African sleeping sickness... Nov 7, 2007 Vancouver, British Columbia– November 7, 2007– Upstream Biosciences Inc. (OTCBB: UPBS) today announced it is establishing a Chemoinformatics Program to extend its drug discovery efforts into additional disease areas. Upstream’s Chemoinformatics Program combines artificial intelligence, advanced computational methods and chemical diversity techniques that will be applied to the company's proprietary drug scaffolds and compound library... MEDIA - Oct 30, 2007 A Vancouver company is partnering with the Ugandan government
to develop compounds to treat tropical parasitic diseases that are endemic
in parts of Africa.... Oct 29, 2007
Oct 15, 2007 Photo Above (left to right): Joel Bellenson (CEO Upstream Biosciences Inc. & Keynote Speaker), Ann Babumba (Upstream Ugandan consultant), Hon. Dr. Stephen Mallinga (Minister of Health), Dr. Lawrence Kaggwa (Dir. Health Service Planning and Development), Dr. Amandua Jacinto (Commissioner, Clinical Services) VANCOUVER, BRITISH COLUMBIA—(Marketwire - Oct. 15, 2007) - Upstream Biosciences Inc. (OTCBB:UPBS) today announced that the Ministry of Health of Uganda has issued a letter of intent confirming its plans to collaborate with Upstream on the development of the company's novel therapeutic compounds to treat topical parasitic diseases, focusing initially on African sleeping sickness and leishmaniasis... Oct 2, 2007 Vancouver, British Columbia– Upstream Biosciences Inc. (OTCBB: UPBS) today announced that its Chief Executive Officer, Joel L. Bellenson, will unveil Upstream’s promising new drug candidates in a keynote address to the International Scientific Council for Trypanosomiasis Research and Control (ISCTRC) conference being held in Angola from October 1 to 5, 2007... Oct 1 , 2007 (PRESS RELEASE) (INVITATION AS KEYNOTE SPEAKER) Aug 27, 2007 Vancouver, British Columbia– August 27, 2007– Upstream Biosciences Inc. (OTCBB: UPBS) today announced it has completed the acquisition of Pacific Pharma Technologies Inc., an early stage biopharmaceutical company with a proprietary technology platform that combines artificial intelligence, advanced computational methods and chemical diversity techniques to discover new drugs. This technology has already generated novel compounds that in laboratory studies demonstrate both human and veterinary potential against major tropical parasitic diseases... Aug 16, 2007 Vancouver, British Columbia– August 16, 2007– Upstream Biosciences Inc. (OTCBB: UPBS), today announced it has signed an agreement with Analytical Biological Services, Inc. (ABS), to supply tissue samples to further the development of the Upstream biomarker program... July 16, 2007 Vancouver, British Columbia– July 16, 2007– Upstream Biosciences Inc. (OTCBB: UPBS), today announced it has hired GendeLLindheim BioCom Partners, LLC, as its communications agency of record... July 9, 2007 July 9, 2007 – Upstream Biosciences Inc. (OTCBB: UPBS), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, today announced that it has retained Genpathway, Inc. to conduct analysis using its highly sensitive chromatin immunoprecipitation assays... May 14, 2007 May 14, 2007 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced today the appointment of Mr. Edward Kiruluta to its scientific advisory board... May 7, 2007 May 7, 2007 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), is pleased to announce that the Company has successfully closed the second and final tranche of its unit financing announced on February 26, 2007... April 30, 2007 April 30th, 2007 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has appointed Dr. Dale Pfost to the Company’s board of directors. Dr. Pfost is currently President of Opko Health and former CEO of Acuity Pharmaceuticals, Orchid BioSciences, and Oxford GlycoSciences... April 2, 2007 April 2, 2007 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has appointed NimbleGen Systems, Inc. to provide Upstream with laboratory services using NimbleGen's whole genome chromatin immunoprecipitation (ChIP)-chip arrays and laboratory services to validate Upstream’s in silico binding site predictions, which marks the commencement of an important phase of our biomarker validation process... Mar 28, 2007 March 28, 2007 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, announces a provisional patent filing of prostate cancer biomarkers that could be useful for determining the course of treatment for prostate cancer patients. This filing meets the Company’s fourth milestone related to the recent financing announced March 5, 2007... Mar 27, 2007 March 27, 2007 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has appointed Philip Rice, former Treasurer for Transamerica and former Director of Dresdner Kleinworth Wasserstein to the Company’s board of directors... Mar 21, 2007 VANCOUVER, BC - March 21, 2007 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced that it has been granted membership to the trade association Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and 31 other nations... Mar 19, 2007 March 19, 2007 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has signed an option agreement to acquire Pacific Pharma Technologies Inc. The agreement gives Upstream a 3-month exclusive option period to conduct due diligence and negotiate the terms of the acquisition transaction... Mar 16, 2007 Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced that the Company has converted the debenture issued by Novar Capital Corp... Mar 5, 2007 Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), has announced that the Company has secured a $2M equity financing. Under the terms of the deal, Upstream has received $1M in immediate financing and will receive $1M within 30 days contingent on the successful completion of corporate milestones... Feb 16, 2007 LifeSciences BC Supports and Represents One of Top Biotech Communities in North America February 16, 2007 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced that the Company has been accepted to join LifeSciences British Columbia, formerly known as BC Biotech... Feb 5, 2007 February 5, 2007 - Upstream Biosciences Inc. (OTCBB:UPBS) (“Upstream” or the “Company”), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has named Libby Communications, Inc., as its public relations agency of record...
November 13, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, is pleased to announce that Joel Bellenson, CEO of Upstream Biosciences Inc. and Dexster Smith, president of Upstream Biosciences Inc. will be attending the 2nd Annual Burrill Personalized Medicine Meeting in San Francisco, California on November 13th and 14th and will be staying in San Francisco for the remainder of the week for meetings... Oct 6, 2006 October 6, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or the "Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, is pleased to announce that, on October 3, 2006, it signed a sample acquisition agreement with JTAT, a Vancouver, Canada based biotechnology consulting firm... Sept 26, 2006 September 26, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, is pleased to announce that, on September 25, 2006 it filed a provisional patent application with the U.S. Patent and Trademark Office for certain thyroid cancer biomarkers that could be useful for determining whether patients have a genetic risk of developing thyroid cancer... Sept 13, 2006 September 13, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, is pleased to announce that, on September 12, 2006, it filed a provisional patent application with the U.S. Patent and Trademark Office for certain ovarian cancer biomarkers that could be useful for determining whether patients have a genetic risk of developing ovarian cancer... Aug 31, 2006 August 31, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, announced today the signing of a letter of engagement with Atlas Capital Services, LLC of New York ("Atlas") to act as its investment banker... June 14, 2006 June 14, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced today the appointment of Dr. Robert D. Sindelar to its scientific advisory board... May 24, 2006 May 24, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced today the appointment of Dr. Brett Casey to its scientific advisory board. Dr. Casey is the Director of the Molecular Genetics Laboratory at British Columbia's Children's Hospital... May 8, 2006 May 8th, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced today that it entered into a lease agreement with the BC Cancer Agency... April 26, 2006 April 26, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced today the appointment of Dr. Artem Cherkasov to its scientific advisory board... April 12, 2006 April 12, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, is pleased to announce the appointment of Tim Fernback as CFO of the Company... April 3, 2006 April 3, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced today the provisional patent filing of prostate cancer biomarkers that could be useful for determining patients with a genetic risk of developing prostate cancer... Mar 21, 2006 March 21, 2006 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced today the appointment of Dr. Wyeth Wasserman to its scientific advisory board... Mar 03, 2006 VANCOUVER, British Columbia, Mar 03, 2006 (BUSINESS WIRE)
-- |
|
